Key Points
- Replimune Director Kapil Dhingra sold 21,500 shares for $408,500, at an average price of $19 per share. The sale covered tax withholding obligations tied to vested equity awards; he retained 21,669 shares.
- Replimune reported a quarterly loss of $0.54 per share, better than analysts’ expected loss of $0.78. Analysts’ consensus rating is “Moderate Buy,” with an average price target of $14.33.
- The stock opened at $20.65 and recently traded near its 52-week high of $21.26; institutional investors own 92.53% of the company’s shares.
Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) Director Kapil Dhingra sold 21,500 shares of the company's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $19.00, for a total transaction of $408,500.00. Following the transaction, the director owned 21,669 shares in the company, valued at approximately $411,711. This trade represents a 49.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Replimune Group Price Performance
Shares of Replimune Group stock opened at $20.65 on Wednesday. The company has a quick ratio of 6.90, a current ratio of 7.11 and a debt-to-equity ratio of 0.59. The company has a 50 day moving average price of $13.79 and a 200 day moving average price of $9.47. Replimune Group, Inc. has a 52 week low of $1.50 and a 52 week high of $21.26.
Replimune Group (NASDAQ:REPL - Get Free Report) last released its earnings results on Wednesday, October 28th. The company reported ($0.54) EPS for the quarter, topping analysts' consensus estimates of ($0.78) by $0.24. As a group, equities research analysts predict that Replimune Group, Inc. will post -2.40 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Replimune Group
A number of institutional investors have recently modified their holdings of REPL. AXQ Capital LP grew its stake in shares of Replimune Group by 4.1% during the 2nd quarter. AXQ Capital LP now owns 27,121 shares of the company's stock worth $300,000 after purchasing an additional 1,056 shares during the period. Walleye Capital LLC increased its holdings in shares of Replimune Group by 3.2% during the 1st quarter. Walleye Capital LLC now owns 71,592 shares of the company's stock valued at $548,000 after purchasing an additional 2,192 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Replimune Group by 30.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,191 shares of the company's stock valued at $223,000 after purchasing an additional 4,050 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Replimune Group during the 3rd quarter valued at approximately $64,000. Finally, Allworth Financial LP acquired a new position in shares of Replimune Group in the 2nd quarter valued at $62,000. Hedge funds and other institutional investors own 92.53% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on the stock. Weiss Ratings downgraded shares of Replimune Group from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, August 11th. Wall Street Zen raised shares of Replimune Group from a "sell" rating to a "hold" rating in a report on Saturday. JPMorgan Chase & Co. upped their target price on Replimune Group from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Wednesday, August 26th. Piper Sandler raised Replimune Group from a "hold" rating to a "strong-buy" rating in a research report on Friday, July 31st. Finally, Wedbush upgraded Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 target price for the company in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $14.33.
Check Out Our Latest Stock Report on REPL
Replimune Group Company Profile
(
Get Free Report)
Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company's approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.
Replimune's lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
